A randomized, double-blind, placebo-controlled, multicenter, Phase II study to assess the efficacy and safety of filgotinib administered for 12 weeks to subjects with active ankylosing spondylitis

Trial Profile

A randomized, double-blind, placebo-controlled, multicenter, Phase II study to assess the efficacy and safety of filgotinib administered for 12 weeks to subjects with active ankylosing spondylitis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2018

At a glance

  • Drugs Filgotinib (Primary)
  • Indications Ankylosing spondylitis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms TORTUGA
  • Sponsors Galapagos NV
  • Most Recent Events

    • 02 Aug 2018 According to a Galapagos NV media release, top-line results from this study is expected in the third quarter 2018.
    • 28 Jul 2018 This trial has been completed in Spain.
    • 21 Jul 2018 This trial has been completed in Bulgaria (End date: 2018-07-02), according to European Clinical Trials Database
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top